Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ayr Wellness Inc. (AYRWF)
USD0.01
0.00 (-8.33%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
2601 South Bayshore Drive 33133
Miami, FL, US
Miami, FL, US
CEO
Blake Holzgrafe
Website
ayrwellness.com
IPO
2020-12-04
CIK 1847462 ISIN CA05475P1099
Also trades on
Canadian Securities Exchange · AYR-A.CN (CAD)
Other OTC · AYRWF (USD)
Description
Ayr Wellness Inc. cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods in United States. The company engages in the possession, manufacture, use, sale, or distribution of cannabis and/or holding of licenses in the adult-use and/or medicinal cannabis marketplace. Its portfolio includes consumer-packaged goods under the kynd, HAZE, and Later Days brand names, as well as legacy and local brands. The company also owns and operates a chain of cannabis retail stores under AYR and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.01
0.00 (-8.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
241.0K
Beta
1.01
Float Shares
93.46M
Free Float %
80.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +26.44% | +49.66% | +74.60% | -4.56% | +193.33% | +10.00% | -80.00% | -98.00% | -99.92% | -99.90% | -99.90% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
0.01
Low
1.00
+8,990.9%
Consensus
1.00
+8,990.9%
Median
1.00
+8,990.9%
High
1.00
+8,990.9%
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
3.88
+35,172.7%
|
Quality scores
Altman Z-Score
-1.63
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.0% Q1'25: -9.1% (vs Q1'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+12.0% Q1'25: +54.6% (vs Q1'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-53.7% Q1'25: +5.6% (vs Q1'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-51.9% Q1'25: -18.5% (vs Q1'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-25.3% Q1'25: -8.7% (vs Q1'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+49.6% Q1'25: +19.3% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-4.02× Q1'25: 139.72× (vs Q1'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
722.6K
est: 78.68M (-99.1%)
|
75.20M
est: 78.73M (-4.5%)
|
155.11M
est: 155.02M (+0.1%)
|
357.61M
est: 354.08M (+1.0%)
|
421.44M
est: 466.57M (-9.7%)
|
463.63M
est: 475.87M (-2.6%)
|
463.63M
est: 456.43M (+1.6%)
|
449.00M
est.
|
455.44M
455.44M – 455.44M
+1.4% YoY
|
545.74M
545.74M – 545.74M
+19.8% YoY
|
507.13M
507.13M – 507.13M
-7.1% YoY
|
531.24M
531.24M – 531.24M
+4.8% YoY
|
| EBITDA |
—
est: 3.60M (-100.0%)
|
-146.00M
est: 3.60M (-4,151.9%)
|
20.70M
est: 7.09M (+191.8%)
|
87.69M
est: 16.21M (+441.1%)
|
-993.0K
est: 21.35M (-104.7%)
|
86.15M
est: 21.78M (+295.6%)
|
-154.53M
est: 20.89M (-839.7%)
|
20.55M
est.
|
20.84M
20.84M – 20.84M
+1.4% YoY
|
24.98M
24.98M – 24.98M
+19.8% YoY
|
23.21M
23.21M – 23.21M
-7.1% YoY
|
24.31M
24.31M – 24.31M
+4.8% YoY
|
| EBIT |
-7.25M
est: -9.58M (+24.3%)
|
-156.31M
est: -9.59M (-1,530.4%)
|
4.17M
est: -18.88M (+122.1%)
|
28.86M
est: -43.12M (+166.9%)
|
-77.14M
est: -56.81M (-35.8%)
|
-6.35M
est: -57.95M (+89.0%)
|
-240.83M
est: -55.58M (-333.3%)
|
-54.68M
est.
|
-55.46M
-55.46M – -55.46M
-1.4% YoY
|
-66.45M
-66.45M – -66.45M
-19.8% YoY
|
-61.75M
-61.75M – -61.75M
+7.1% YoY
|
-64.69M
-64.69M – -64.69M
-4.8% YoY
|
| Net Income |
-36.51M
est: 59.92M (-160.9%)
|
-164.18M
est: -226.46M (+27.5%)
|
-24.61M
est: -102.28M (+75.9%)
|
-16.95M
est: -87.99M (+80.7%)
|
-245.47M
est: -161.56M (-51.9%)
|
-272.43M
est: -126.76M (-114.9%)
|
-359.31M
est: -217.07M (-65.5%)
|
-146.76M
est.
|
-132.20M
-132.20M – -132.20M
+9.9% YoY
|
-83.70M
-83.70M – -83.70M
+36.7% YoY
|
-67.65M
-67.65M – -67.65M
+19.2% YoY
|
-61.92M
-61.92M – -61.92M
+8.5% YoY
|
| SGA |
7.98M
est: 33.63M (-76.3%)
|
47.35M
est: 33.66M (+40.7%)
|
71.73M
est: 66.27M (+8.2%)
|
144.44M
est: 151.36M (-4.6%)
|
222.09M
est: 199.45M (+11.4%)
|
177.80M
est: 203.42M (-12.6%)
|
167.13M
est: 195.11M (-14.3%)
|
191.94M
est.
|
194.69M
194.69M – 194.69M
+1.4% YoY
|
233.29M
233.29M – 233.29M
+19.8% YoY
|
216.78M
216.78M – 216.78M
-7.1% YoY
|
227.09M
227.09M – 227.09M
+4.8% YoY
|
| EPS |
-12.36
est: 0.54 (-2,386.3%)
|
-6.15
est: -2.04 (-201.0%)
|
-0.88
est: -0.92 (+4.6%)
|
-0.29
est: -0.79 (+63.5%)
|
-3.43
est: -1.46 (-135.3%)
|
-3.68
est: -1.14 (-221.8%)
|
-3.24
est: -1.96 (-65.4%)
|
-1.32
est.
|
-1.19
-1.19 – -1.19
+9.9% YoY
|
-0.76
-0.76 – -0.76
+36.7% YoY
|
-0.61
-0.61 – -0.61
+19.2% YoY
|
-0.56
-0.56 – -0.56
+8.5% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-20.91M
OE per share TTM
-0.18
Owner's Yield
-802.79%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
102.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
3
Total invested
8.2K
Insider transactions (90d)
0
Beneficial owners (>5%)
2
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nomura Global Financial Products, Inc. | 4.77M | 8.10% | — | 4.77M | — | 4.77M | BD | Japan | 2023-02-14 | ↗ |
| 2 | Nomura Holdings, Inc. | 4.77M | 8.10% | — | 4.77M | — | 4.77M | HC | Japan | 2023-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
3
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FIRST NATIONAL TRUST CO | 511.0K +— (+0.0%) | 8.0K -2.2K (-21.5%) | 0.44% +0.000 pp | 0.00% 0.000 pp | USD1.99 -99.0% | 16 qtrs — |
| 2 | ALBERT D MASON INC | 12.9K -659.0 (-4.8%) | 203.00 -69.0 (-25.4%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD2.37 -99.2% | 15 qtrs — |
| 3 | BYRNE ASSET MANAGEMENT LLC | 1.2K +— (+0.0%) | 18.00 -5.0 (-21.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.18 -99.9% | 18 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-101.2K
Shares Outstanding
116.77M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Julie Winter | Interim Co-Chief Revenue Officer | 913.8K | female |
| Paul Fisher | Chief Transformation Officer | 600.0K | — |
| Khari Edwards | Head of CSR | — | — |
| Mark Bruno | Senior Vice President of Cultivation | — | — |
| Sarvesh Mathur | Chief Technology Officer | — | male |
| Anya Varga | Chief People Officer | — | female |
| Scott J. Davido | Interim Chief Executive Officer | — | male |
| George Frank DeNardo | Chief Operating Officer & President | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AYRWF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
